Stay updated with breaking news from Patients Treated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The panel concludes by discussing the long-term outcomes for patients treated for hypercortisolism, emphasizing the need for further studies and data, and sharing their final thoughts on the disease and its future management.
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...
/PRNewswire/ - Medunik USA, member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global...
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median...
-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -